Amgen's MariTide Drug Promises Long-Term Weight Loss with Monthly Injections
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 14 2026
0mins
Should l Buy AMGN?
Source: CNBC
- Weight Loss Innovation: Amgen's experimental GLP-1 drug MariTide demonstrated in trials that patients can maintain weight loss for two years with monthly injections, significantly improving patient adherence and long-term success rates compared to current weekly options.
- Injection Frequency Optimization: Bradway indicated that MariTide could be administered monthly or even quarterly, greatly enhancing treatment convenience for patients and potentially driving increased market demand for the drug.
- In-Depth Dose Research: Amgen is studying the efficacy of various doses to determine what it takes for patients to remain on therapy, with Bradway emphasizing that “persistence is the name of the game,” which will directly impact the drug's market performance and company revenues.
- Successful Acquisition Integration: Amgen's acquisition of Horizon Therapeutics is progressing well, with Bradway noting that the new medicines primarily target autoimmune diseases and are largely biologics, aligning with the company's strengths and potentially expanding into more indications to increase market share.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AMGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AMGN
Wall Street analysts forecast AMGN stock price to fall
24 Analyst Rating
14 Buy
9 Hold
1 Sell
Moderate Buy
Current: 385.700
Low
280.00
Averages
363.10
High
425.00
Current: 385.700
Low
280.00
Averages
363.10
High
425.00
About AMGN
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Chronic Kidney Disease Market Growth Drivers
- Market Size Growth: According to analysis, the chronic kidney disease (CKD) market size was approximately $4.8 billion in 2024 and is expected to grow further by 2034, reflecting increased demand for new therapies and an expanding patient base.
- Rising Patient Numbers: In 2024, there were about 82 million prevalent cases of CKD across the 7 major markets (7MM), with projections indicating continued growth from 2025 to 2034, primarily driven by an aging population and the rising prevalence of diabetes and hypertension.
- Launch of New Therapies: The introduction of emerging therapies such as AstraZeneca's Zibotentan/Dapagliflozin and Boehringer Ingelheim's Vicadrostat + Empagliflozin is expected to significantly boost market growth and improve treatment outcomes for patients.
- Advancements in Biomarkers: Progress in biomarkers like KIM-1 and NGAL enables more precise early detection of CKD, thereby enhancing the potential for timely interventions and improving overall patient prognosis.
See More
ImmunityBio Earnings Preview and Market Reaction
- Earnings Expectations: ImmunityBio is projected to report FY2025 revenue of $113.3 million, a staggering 700% increase from $14.8 million in 2024, while losses per share are expected to improve to $0.38, indicating significant progress in its commercialization efforts.
- Anktiva's Strong Performance: Anktiva generated $113 million in net product revenue for 2025, marking a 700% year-over-year increase, with Q4 revenue soaring 431% to $38.3 million, surpassing market expectations and reflecting robust demand in the market.
- Promotion of IL-15 Mechanism: Founder Soon-Shiong has highlighted Anktiva's IL-15 mechanism in media appearances, emphasizing its potential in cancer treatment, particularly in combination with Merck's Keytruda, which may enhance efficacy and improve cancer-free rates for patients.
- Optimistic Market Sentiment: On Stocktwits, retail sentiment for IBRX has turned 'bullish' amid a 185% surge in message volume over 24 hours, with investors expressing optimistic price predictions that could drive the stock price rapidly upward, with some users forecasting it could reach $20.
See More
Couple's Financial Manifesto Revisited and Market Insights
- Dow Jones Milestone: On February 6, 2026, the Dow Jones Industrial Average surpassed 50,000 for the first time, marking a 25% increase from 40,000 less than two years ago, outperforming both the S&P 500 and NASDAQ, which reflects a resurgence of investor confidence and stability in turbulent economic times.
- Mixed Job Market Signals: The U.S. Bureau of Labor Statistics reported a 130,000 increase in non-farm payrolls for January, more than double the expected 60,000, with the unemployment rate dropping to 4.3%; however, most new jobs were concentrated in healthcare and social assistance, indicating an uneven economic recovery.
- Rising Government Debt: The Congressional Budget Office projects that the U.S. government will overspend by $5.8 trillion in 2026, with this figure expected to rise to $6 trillion by 2036, pushing federal debt to 120% of GDP, which poses significant challenges to fiscal sustainability and long-term economic health.
- Importance of Financial Management: Robert and Elizabeth Brokamp discussed their financial manifesto created 26 years ago, emphasizing the necessity of regular financial check-ins to prevent marital discord due to financial disagreements, highlighting the critical role of effective financial communication in maintaining family harmony.
See More
Revisiting the Couple's Financial Manifesto
- Dow Jones Milestone: On February 6, 2026, the Dow Jones Industrial Average surpassed 50,000 for the first time, marking a 25% increase from 40,000 less than two years ago, indicating strong recent performance driven by high allocations in industrials and energy sectors.
- Job Market Signals: The U.S. Bureau of Labor Statistics reported a 130,000 increase in non-farm payrolls for January 2026, more than double the expected 60,000, with the unemployment rate dropping to 4.3%, reflecting positive economic recovery signals, although most new jobs were in healthcare and social assistance.
- Government Deficit: According to the Congressional Budget Office, the U.S. government will spend $5.8 trillion more than it collects in taxes and tariffs in 2026, with projections indicating this annual deficit could rise to $6 trillion by 2036, highlighting ongoing fiscal pressures and reliance on borrowing.
- Importance of Financial Planning: Robert and Elizabeth Brokamp discussed their financial manifesto created 26 years ago, emphasizing the need for regular check-ins on financial goals and priorities to prevent financial disagreements that can lead to marital discord.
See More
Amgen Inc. Shows Bullish Outlook with Strong Fundamentals
- Stock Performance: As of February 23, 2026, Amgen Inc. (AMGN) shares traded at $376, reflecting a 36.41% appreciation since our last coverage in May 2025, indicating strong market confidence and growth potential.
- Financial Metrics: With trailing and forward P/E ratios of 24.32 and 13.74 respectively, alongside projected 2026 revenues of approximately $38.4 billion, Amgen demonstrates compelling growth prospects in the biotech sector.
- Options Market Signal: A trader sold 1,000 June 18, 2026 $340 put contracts for $9.00 each, collecting $900,000 in upfront premium, reflecting market confidence in Amgen's future performance.
- Cash Flow and Dividends: Amgen boasts around $9.1 billion in cash and a 2.6% dividend yield, enhancing its financial stability while providing funding support for future growth.
See More
VivaVision Races for Hong Kong IPO to Sustain Cash Flow
- Clinical Trial Progress: VivaVision's two drugs have reached Phase Three clinical trials, with one receiving regulatory fast track designation as a breakthrough therapy for eye inflammation, indicating its potential in the ophthalmic treatment sector.
- Increasing Financial Pressure: As of September 2025, the company had only 35.77 million yuan ($5.2 million) in cash, while net losses for the first three quarters of 2025 reached 131 million yuan, averaging about 43.33 million yuan per quarter, compelling the company to list quickly to replenish its funds.
- Funding History: Over its funding rounds, VivaVision has raised approximately 735 million yuan, with its valuation soaring from 17 million yuan to nearly 1.83 billion yuan, reflecting investor confidence in its long-term potential for innovative eye care solutions.
- Intense Market Competition: Despite advancements in eye inflammation treatment, the dry eye therapy market is highly competitive, with five innovative drugs already approved in China and another ten candidates at Phase Two or beyond, posing significant commercialization challenges.
See More
Chronic Kidney Disease Market Growth Drivers
- Market Size Growth: According to analysis, the chronic kidney disease (CKD) market size was approximately $4.8 billion in 2024 and is expected to grow further by 2034, reflecting increased demand for new therapies and an expanding patient base.
- Rising Patient Numbers: In 2024, there were about 82 million prevalent cases of CKD across the 7 major markets (7MM), with projections indicating continued growth from 2025 to 2034, primarily driven by an aging population and the rising prevalence of diabetes and hypertension.
- Launch of New Therapies: The introduction of emerging therapies such as AstraZeneca's Zibotentan/Dapagliflozin and Boehringer Ingelheim's Vicadrostat + Empagliflozin is expected to significantly boost market growth and improve treatment outcomes for patients.
- Advancements in Biomarkers: Progress in biomarkers like KIM-1 and NGAL enables more precise early detection of CKD, thereby enhancing the potential for timely interventions and improving overall patient prognosis.
See More
ImmunityBio Earnings Preview and Market Reaction
- Earnings Expectations: ImmunityBio is projected to report FY2025 revenue of $113.3 million, a staggering 700% increase from $14.8 million in 2024, while losses per share are expected to improve to $0.38, indicating significant progress in its commercialization efforts.
- Anktiva's Strong Performance: Anktiva generated $113 million in net product revenue for 2025, marking a 700% year-over-year increase, with Q4 revenue soaring 431% to $38.3 million, surpassing market expectations and reflecting robust demand in the market.
- Promotion of IL-15 Mechanism: Founder Soon-Shiong has highlighted Anktiva's IL-15 mechanism in media appearances, emphasizing its potential in cancer treatment, particularly in combination with Merck's Keytruda, which may enhance efficacy and improve cancer-free rates for patients.
- Optimistic Market Sentiment: On Stocktwits, retail sentiment for IBRX has turned 'bullish' amid a 185% surge in message volume over 24 hours, with investors expressing optimistic price predictions that could drive the stock price rapidly upward, with some users forecasting it could reach $20.
See More
Couple's Financial Manifesto Revisited and Market Insights
- Dow Jones Milestone: On February 6, 2026, the Dow Jones Industrial Average surpassed 50,000 for the first time, marking a 25% increase from 40,000 less than two years ago, outperforming both the S&P 500 and NASDAQ, which reflects a resurgence of investor confidence and stability in turbulent economic times.
- Mixed Job Market Signals: The U.S. Bureau of Labor Statistics reported a 130,000 increase in non-farm payrolls for January, more than double the expected 60,000, with the unemployment rate dropping to 4.3%; however, most new jobs were concentrated in healthcare and social assistance, indicating an uneven economic recovery.
- Rising Government Debt: The Congressional Budget Office projects that the U.S. government will overspend by $5.8 trillion in 2026, with this figure expected to rise to $6 trillion by 2036, pushing federal debt to 120% of GDP, which poses significant challenges to fiscal sustainability and long-term economic health.
- Importance of Financial Management: Robert and Elizabeth Brokamp discussed their financial manifesto created 26 years ago, emphasizing the necessity of regular financial check-ins to prevent marital discord due to financial disagreements, highlighting the critical role of effective financial communication in maintaining family harmony.
See More
Revisiting the Couple's Financial Manifesto
- Dow Jones Milestone: On February 6, 2026, the Dow Jones Industrial Average surpassed 50,000 for the first time, marking a 25% increase from 40,000 less than two years ago, indicating strong recent performance driven by high allocations in industrials and energy sectors.
- Job Market Signals: The U.S. Bureau of Labor Statistics reported a 130,000 increase in non-farm payrolls for January 2026, more than double the expected 60,000, with the unemployment rate dropping to 4.3%, reflecting positive economic recovery signals, although most new jobs were in healthcare and social assistance.
- Government Deficit: According to the Congressional Budget Office, the U.S. government will spend $5.8 trillion more than it collects in taxes and tariffs in 2026, with projections indicating this annual deficit could rise to $6 trillion by 2036, highlighting ongoing fiscal pressures and reliance on borrowing.
- Importance of Financial Planning: Robert and Elizabeth Brokamp discussed their financial manifesto created 26 years ago, emphasizing the need for regular check-ins on financial goals and priorities to prevent financial disagreements that can lead to marital discord.
See More
Amgen Inc. Shows Bullish Outlook with Strong Fundamentals
- Stock Performance: As of February 23, 2026, Amgen Inc. (AMGN) shares traded at $376, reflecting a 36.41% appreciation since our last coverage in May 2025, indicating strong market confidence and growth potential.
- Financial Metrics: With trailing and forward P/E ratios of 24.32 and 13.74 respectively, alongside projected 2026 revenues of approximately $38.4 billion, Amgen demonstrates compelling growth prospects in the biotech sector.
- Options Market Signal: A trader sold 1,000 June 18, 2026 $340 put contracts for $9.00 each, collecting $900,000 in upfront premium, reflecting market confidence in Amgen's future performance.
- Cash Flow and Dividends: Amgen boasts around $9.1 billion in cash and a 2.6% dividend yield, enhancing its financial stability while providing funding support for future growth.
See More
VivaVision Races for Hong Kong IPO to Sustain Cash Flow
- Clinical Trial Progress: VivaVision's two drugs have reached Phase Three clinical trials, with one receiving regulatory fast track designation as a breakthrough therapy for eye inflammation, indicating its potential in the ophthalmic treatment sector.
- Increasing Financial Pressure: As of September 2025, the company had only 35.77 million yuan ($5.2 million) in cash, while net losses for the first three quarters of 2025 reached 131 million yuan, averaging about 43.33 million yuan per quarter, compelling the company to list quickly to replenish its funds.
- Funding History: Over its funding rounds, VivaVision has raised approximately 735 million yuan, with its valuation soaring from 17 million yuan to nearly 1.83 billion yuan, reflecting investor confidence in its long-term potential for innovative eye care solutions.
- Intense Market Competition: Despite advancements in eye inflammation treatment, the dry eye therapy market is highly competitive, with five innovative drugs already approved in China and another ten candidates at Phase Two or beyond, posing significant commercialization challenges.
See More
